




Therapy Gene therapy with *hokD* and *ldrB* genes for cancer treatment

A research group of the Public Health System of Andalusia (SSPA) has developed an alternative technology, based on the transfection of *hokD* and *ldrB* genes, to be used in cancer gene therapy.

Oficina de
**TRANSFERENCIA
DE TECNOLOGÍA**
Sistema Sanitario Público de Andalucía



Description

Due to the high prevalence of cancer in recent years, it is necessary the devolvement of new and more effective therapies which produce fewer side effects. Development of gene therapy for cancer based on the use of suicide genes that can damage the tumor cell and not require a prodrug for its lethal effect is one of the aims of new gene therapy strategies.

The disclosed invention is related to the isolated RNA or DNA polynucleotides from *hokD* and *ldrB* genes for gene therapy of cancer treatment.



Intellectual Property

The present invention is protected by worldwide patent.



Aims

- ✓ Exploitation license agreement
- ✓ Public-private partnership agreement for the co-development of the technology.



Advantages

- ✓ Induction of *hokD* and *ldrB* genes expression produced morphological changes and induced a clear antiproliferative effect in cancer cells.
- ✓ High therapeutic value.
- ✓ Versatile system.
- ✓ Development of site-selective vectors for gene therapy: experimental protocols making use of cell type- or tissue-specific promoters.
- ✓ Strategy considered as candidate for suicide gene therapy in the future.



Clasificación

Area: Therapy.
Technology: Gene therapy
Pathology: Oncology.